Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDK1 | Q15118 | 8/20 | 0.41 |
| ▸ | IRAK4 | Q9NWZ3 | 4/20 | 0.36 |
| ▸ | EPHA2 | P29317 | 3/20 | 0.34 |
| ▸ | EPHB4 | P54760 | 2/20 | 0.33 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.33 |
| ▸ | KDR | P35968 | 1/20 | 0.33 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.33 |
| ▸ | DRD4 | P21917 | 1/20 | 0.33 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22320559 | 1.00 | PDK1 (0.41) | PDK1IRAK4EPHA2EPHB4HRH3 | |
| SCHEMBL28562168 | 0.90 | EPHA2 (0.43) | PDK1EPHA2EPHB4ERBB2 | |
| SCHEMBL28562167 | 0.90 | EPHA2 (0.43) | PDK1EPHA2EPHB4ERBB2 | |
| SCHEMBL22320570 | 0.85 | HRH3 (0.44) | PDK1IRAK4EPHA2EPHB4HRH3 | |
| SCHEMBL22320574 | 0.85 | HRH3 (0.44) | PDK1IRAK4EPHA2EPHB4HRH3 | |
| SCHEMBL22320757 | 0.82 | HRH3 (0.45) | PDK1IRAK4EPHA2EPHB4HRH3 | |
| SCHEMBL22320756 | 0.82 | HRH3 (0.45) | PDK1IRAK4EPHA2EPHB4HRH3 | |
| SCHEMBL22262485 | 0.81 | HRH3 (0.39) | PDK1IRAK4EPHA2HRH3DRD4 | |
| SCHEMBL22262484 | 0.81 | HRH3 (0.39) | PDK1IRAK4EPHA2HRH3DRD4 | |
| SCHEMBL15414558 | 0.79 | PDK1 (0.45) | PDK1EPHA2EPHB4HRH3KDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200255451-A1 | MACROCYCLIC MCL-1 INHIBITORS AND METHODS OF USE | ABBVIE INC (US) | 2020-08-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200255451-A1 | MACROCYCLIC MCL-1 INHIBITORS AND METHODS OF USE | MCL1, BCL2A1, BCL2L10 | PDK1 2477/4885IRAK4 1361/4885EPHA2 2661/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.